Chardan Capital analyst Daniil Gataulin initiates coverage on EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Buy rating and announces Price Target of $21.
Here’s How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 5 Years
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 5 years by 11.39% on an annualized basis…